Filing identity and period
Important mismatch: The request identifies TERAWULF INC., but the supplied Form 10-Q is for IKONICS CORPORATION (Nasdaq: IKNX), for the quarter ended June 30, 2019. The figures below summarize the supplied filing, not TeraWulf.
The unaudited report covers the second quarter and first six months of 2019, with comparisons to the same periods in 2018. IKONICS reports four segments: Chromaline, IKONICS Imaging, Digital Texturing (DTX), and Advanced Material Solutions (AMS).
Financial performance
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Net sales | $4.596 million | $4.634 million | $8.125 million | $8.706 million |
| Gross profit (margin) | $1.428 million (31.1%) | $1.662 million (35.9%) | $2.438 million (30.0%) | $3.025 million (34.7%) |
| Operating income (loss) | $(181,000) | $197,000 | $(733,000) | $56,000 |
| Net income (loss) | $(116,000) | $145,000 | $(571,000) | $15,000 |
| Basic and diluted EPS | $(0.06) | $0.07 | $(0.29) | $0.01 |
Operating cash flow was negative $769,000 for the first half of 2019, versus positive $878,000 in first-half 2018. Investing activities used $466,000 and financing activities used $91,000; cash and cash equivalents fell by $1.326 million to $297,000.
At June 30, 2019, short-term investments were $2.940 million, total current assets $8.420 million, and current liabilities $1.238 million (a derived current ratio of approximately 6.8). Total debt was $2.887 million, including $131,000 current and $2.755 million long-term; no line-of-credit borrowings were outstanding. Cash plus short-term investments totaled $3.237 million. Stockholders’ equity was $12.523 million.
Changes and drivers
- Q2 sales declined 0.8% year over year; first-half sales declined 6.7%. First-half declines were reported in Chromaline, AMS, and IKONICS Imaging, partly offset by DTX growth.
- Gross margin contracted in both comparison periods. Management cited Chromaline’s less favorable mix, higher raw-material and manufacturing costs, and lower AMS sales volumes; DTX margins also fell. Q2 AMS margin improved year over year as costs declined.
- First-half SG&A rose 2.4% to $2.721 million, primarily due to higher health-insurance costs. R&D rose 44.7% to $449,000, reflecting additional staffing and patent-related costs.
- First-half operating cash flow was pressured by a $466,000 inventory increase, a $114,000 decrease in accounts payable, and a $182,000 increase in income taxes receivable. Inventory was being built for expected remainder-of-year demand as first-half sales were below expectations.
Outlook, risks, and unusual items
- No specific revenue or earnings forecast is provided. Management expects to continue R&D and product development, pursue growth in AMS and DTX, and develop products and markets in its established businesses. It cited three long-term AMS sales agreements with major aerospace companies and positive initial reviews and sales for the IKONART product.
- Management expected approximately $346,000 of additional 2019 capital expenditures, for coating capabilities, process improvements, and IT upgrades, to be funded from existing cash and operating cash flow.
- The $2.050 million asset-secured bank credit line was renewed through August 30, 2021, at 1.8 percentage points above 30-day LIBOR. The company reported no outstanding draws and no financial covenants. Management believed available resources and financing capacity would be sufficient for current and anticipated operations.
- Management cited lower sales, customer concentration in AMS, raw-material costs, fixed-cost sensitivity at AMS, and the strong U.S. dollar as relevant business pressures. Foreign sales were 29% of first-half sales, versus 28% in 2018; management said foreign-exchange effects had not been material.
- A $72,000 write-off of previously capitalized patent-application costs was recorded after the company decided not to pursue those applications. The filing reports no legal proceedings, no unrecognized tax benefits, and no off-balance-sheet arrangements. The company stated disclosure controls were effective and reported no material change in internal control over financial reporting.
- IKONICS repurchased 2,742 shares in Q2 for approximately $21,000. Its repurchase authorization allows up to 97,258 additional shares.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is IKONICS Corporation, not TeraWulf Inc.
- Review the causes and persistence of the gross-margin decline and first-half operating loss, particularly Chromaline mix and costs and AMS customer volumes.
- Assess whether inventory build converts to sales and cash, given first-half negative operating cash flow and the sharp decrease in cash balances.
- Verify the timing and funding of planned capital expenditures and the terms and availability of the renewed credit line.
- Monitor progress and commercial contribution from AMS agreements, DTX initiatives, and new products, which the filing describes qualitatively rather than with quantified forecasts.